Neem-based portfolio of new botanical drug products
Neem (Azadirachta indica) is a unique medicinal plant, and its history of therapeutic utility dates back thousands of years and has been in use in traditional Ayurvedic medicine for centuries to treat various diseases. Furthermore, it has been the subject of modern scientific investigations to treat microbial infections, gastric ulcers, cancers, and its immunological and anti-inflammatory activities. Although neem-baed botanical dietary supplement products are marketed globally under the Dietary Supplement Health and Education Act of 1994 (DSHEA), no globally recognized or consensus therapeutic claims or applications exist in modern medicine. In and of itself, this is an unmet need that humanity is not optimally benefiting from this gift of nature. NuAxon Research is leveraging its proprietary supercritical CO2 extracting technology to advance biochemical studies on its proprietary neem extract and clinical studies. It aims to develop a portfolio of new botanical drug products cost-effectively, bridging the gap between a dietary supplement standard and the standard of new botanical drugs, the consistent demonstration of quality, safety, and efficacy.
Considering its immunomodulatory and anti-inflammatory activity during the Covid-19 pandemic, we evaluated the prophylactic activity of neem capsules to prevent COVID-19 infection for persons at high risk of COVID-19 infection. The study found a reduced risk of COVID-19 infection in participants receiving neem capsules, demonstrating its potential as a prophylactic treatment for preventing COVID-19.